BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26366275)

  • 1. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
    Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
    Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
    Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.
    Geng JH; Plym A; Penney KL; Pomerantz M; Mucci LA; Kibel AS
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):320-326. PubMed ID: 35075214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
    Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
    Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS; Koo KC; Cho KS; Chung BH
    Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
    Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
    Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
    Huang FM; Li XH; Liang Y
    Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.